2m 2m 2m 2m 2m 2m 2m
Sigyn Theraptcs (SIGY)
OTC
$0.04+$0.003 (+8.21%)
Price as of Jun 03, 2026- $257.7MMarket Cap
- -98.41%1-Year Change
- BiotechnologyIndustry
Sigyn Theraptcs (SIGY)
$0.04+$0.003 (+8.21%)
Annual
Quarterly
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 1.0B N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 1.0B N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | 1,130 +188.27% | 392 -14.22% | 457 N/A | 0 -100.00% | |
Research and Development Expense | -773,279 -3.12% | -798,165 +21.36% | -657,657 -10.40% | -734,014 +2,573.42% | |
Depreciation and Amortization Expense | 5,611 -16.95% | 6,756 -1.43% | 6,854 +132.65% | 2,946 +751.45% | |
Total Operating Expenses | 2.5M +2.60% | 2.5M +14.35% | 2.1M +6.92% | 2.0M +119.13% | |
Operating Profit | -2.5M +2.60% | -2.5M +14.35% | -2.1M +6.92% | -2.0M +119.13% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -3,382 +40.80% | -2,402 +448.40% | -438 -98.58% | -30,867 -91.00% | |
Interest Income and Expense and Net | -3,382 +40.80% | -2,402 +448.40% | -438 -98.58% | -30,867 -91.00% | |
Total Nonoperating Income and Expense | -820,970 -51.44% | -1.7M +116.04% | -782,552 -21.46% | -996,402 +190.36% | |
Income before Taxes | -3.3M -19.43% | -4.1M +41.51% | -2.9M -2.49% | -3.0M +138.54% | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | 536,047 N/A | |
Net Income | N/A N/A | -4.1M +41.51% | -2.9M -2.49% | -3.0M +138.54% | |
Net Income from Continuing Operations Applicable to Common | -3.3M -19.43% | -4.1M +41.51% | -2.9M -2.49% | -3.0M +138.54% | |
Basic EPS and Net Income | -2.51 -33.42% | -3.77 +4,612.50% | -0.08 0.00% | -0.08 -52.94% | |
Diluted EPS and Net Income | -2.51 -33.42% | -3.77 +4,612.50% | -0.08 0.00% | -0.08 -52.94% | |
Basic Weighted Average Shares | 1.3M +21.09% | 1.1M -97.06% | 37.4M +2.75% | 36.4M +395.11% | |
Diluted Weighted Average Shares | 1.3M +21.09% | 1.1M -97.06% | 37.4M +2.75% | 36.4M +395.11% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 12,144 +3.88% | 11,690 +39.90% | 8,356 -97.55% | 340,956 +303.97% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 12,144 +3.88% | 11,690 +39.90% | 8,356 -97.55% | 340,956 +303.97% | |
Total Current Assets | 21,244 -82.01% | 118,063 +67.95% | 70,298 -82.11% | 393,031 -41.38% | |
Accumulated Depreciation | 22,513 +33.20% | 16,902 +66.59% | 10,146 +208.20% | 3,292 +851.45% | |
Property and Plant and Equipment and Net | 9,685 -36.68% | 15,296 -30.64% | 22,052 -21.37% | 28,046 +1,523.03% | |
Total Long-Term Assets | 70,711 +241.42% | 20,711 0.00% | 20,711 0.00% | 20,711 +1,098.55% | |
Total Assets | 213,719 -33.59% | 321,806 -3.33% | 332,879 -53.13% | 710,259 +2.33% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 2.1M -6.53% | 2.2M +35.05% | 1.6M +152.88% | 647,202 +24.78% | |
Total Current Liabilities | 4.6M +27.91% | 3.6M +76.11% | 2.0M +179.03% | 734,218 +23.42% | |
Total Long-Term Debt | 2.0M -59.68% | 5.0M -7.82% | 5.4M +676.33% | 700,816 +13.68% | |
Total Long-Term Liabilities | 56,356 -55.38% | 126,302 -32.61% | 187,425 -22.11% | 240,625 N/A | |
Total Liabilities | 4.7M +25.09% | 3.7M +67.00% | 2.2M +129.38% | 974,843 +63.87% | |
Retained Earnings | -14.7M +29.45% | -11.3M +57.62% | -7.2M +68.68% | -4.3M +238.25% | |
Total Stockholders Equity | N/A N/A | -3.4M +79.30% | -1.9M +619.33% | -264,584 -366.77% | |
Total Shares Outstanding | 1.6M +24.60% | 1.3M -96.98% | 42.7M +14.53% | 37.3M +5.95% | |
Cash Flow | |||||
Cash from Operating Activities | -872,436 -36.93% | -1.4M -24.42% | -1.8M +3.16% | -1.8M +113.81% | |
Capital Expenditures | N/A N/A | N/A N/A | 860 -97.06% | 29,264 N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | -860 -97.06% | -29,264 +170.99% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 872,890 -37.05% | 1.4M -7.47% | 1.5M -27.26% | 2.1M +122.70% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -0.25% N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | N/A N/A | -1,266.54% +125.47% | -561.73% +31.27% | -427.90% +126.97% | |
Return on Equity | N/A N/A | 155.99% -42.29% | 270.30% -92.56% | 3,633.05% +3,305.63% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 0.005 -85.93% | 0.03 -4.66% | 0.03 -93.59% | 0.54 -52.50% | |
Cash Ratio | 0.003 -18.75% | 0.003 -21.95% | 0.004 -99.12% | 0.46 +227.27% | |
Debt-to-Equity Ratio | N/A N/A | -2.12 -43.06% | -3.72 -27.02% | -5.09 -144.51% | |
Debt-to-Assets Ratio | 19.13 -14.81% | 22.45 +5.61% | 21.26 +1,020.23% | 1.90 +16.04% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow